Zohydro On the Horizon -- The Beginnings of Genix-cide

Pharmaceutical company Zogenix is developing a new "lead product candidate" called Zohydro. If approved and released, this extended-release hydrocodone will allow Big Pharma to introduce government-sponsored "genix-cide" -- deliberate and systematic destruction of an entire group of people.

Here is the strategy developed by Zogenix:

"At Zogenix, our core strategy is to commercialize 

and develop differentiated central nervous system 

(CNS) and pain therapeutics that can address 

significant unmet medical needs and 

overcome limitations of existing products."

According to Zogenix, this is the future of sales generated by Zohydro:

"We (Zogenix) believe Zohydro could 

generate sales from both 

patients who are using 

immediate-release opioid products

on a chronic basis and 

patients already using extended-release opioids."

Read about the product at the Zogenix site: http://www.zogenix.com/index.php/products/zx002/

What is Zohydro?

If approved, it would mark the first time patients could legally buy pure hydrocodone. Existing products combine the drug with nonaddictive painkillers such as acetaminophen. Hydrocodone belongs to family of drugs known as opiates or opioids because they are chemically similar to opium. They include morphine, heroin, oxycodone, codeine, and methadone.

Critics are especially worried about Zohydro, a 12 hour, timed-release drug meant for managing moderate to severe pain, because abusers could crush it for an intense, immediate high. (Pat Dollard, "Zohydro: Painkiller 10 Times Stronger Than Vicodin Causes Concerns," December 26 2011)

Zohydro comes in 10MG, 20MG, 30MG, 40MG and 50MG capsules.

What is "Chronic Pain"?

Zogenix defines chronic pain as "pain that lasts beyond the healing of an injury or that persists beyond three months."

Common types of chronic pain include...

lower back pain, 

arthritis, 

headache and 

face and jaw pain. 

While mild pain does not typically stop an individual from participating in his or her daily activities, moderate pain may prevent an individual from participating in his or her daily activities and severe pain typically stops an individual from participating in his or her daily activities and induces a patient to exhibit pain avoidance behaviors.

Why Could the Product, and Others Like It Unleash Genix-cide? 

Why the new fears for this old yet new drug? Companies such as Zogenix can keep it Schedule III. Why is that important? Less regulation. Not only that, but the sheer amount of opiate can be deadly. It would take 10 times the original hydrocodone painkiller Vicodin (if they were 5/500) to equal one Zohydro. Zohydro with its 50mgs of hydrocodone in a “time release” formula will also be easily crushed and snorted by abusers.
Oxycodone is now the most-abused medicine in the U.S., with hydrocodone second, according to the Drug Enforcement Administration.

Thousands of legitimate pain patients are becoming addicted to these powerful prescription painkillers, they say, in addition to the thousands more who abuse the drugs.

Consider statistics that show emergency room vistis related to hydrocodone abuse have shot from 19,221 in 2000 to 86,258 in 2009, according to the DEA. In Florida alone, hydrocodone caused 910 deaths and contributed to 1,803 others between 2003 and 2007.

The Deadly Deluge Is Coming

Zogenix has completed three rounds of patient testing, and last week it announced it had held a final meeting with FDA officials to talk about its upcoming drug application. It plans to file the application in early 2012 and have Zohydro on the market by early 2013.

The latest drug studies come as more pharmaceutical companies are getting into the $10 billion-a-year legal market for powerful yet highly addictive opioid narcotics. Purdue Pharma and Cephalon, a Frazer, Pa.-based unit of Israel-based Teva Pharmaceuticals, are conducting late-stage trials of their own hydrocodone drugs, according to documents filed with federal regulators. In May, Purdue Pharma received a patent applying extended-release technology to hydrocodone. Egalet has finished the most preliminary stages of safety testing and could have a product on the market as early as 2015 but wants to see how the other companies fare with the FDA before deciding whether to move forward.

“It’s like the wild west,” said Peter Jackson, co-founder of Advocates for the Reform of Prescription Opioids. “The whole supply-side system is set up to perpetuate this massive unloading of opioid narcotics on the American public.” ("New Painkiller Zohydro Worries Abuse Experts," Associated Press Herald Tribune, December 27 2011)

“I have a big concern that this could be the next OxyContin,” said April Rovero, president of the National Coalition Against Prescription Drug Abuse. “We just don’t need this on the market.”

Big Pharma's "Bottom Line"

You just read strategy of Zogenix. Review it and consider the red print. Review the Zogenix belief for the future sales of Zohydro. Again, consider the red print. Lastly, re-read the red print describing the types of chronic pain for which the product is intended.

Sales of prescription opiate narcotics including oxycodone, hydrocodone and others are worth $10 billion per year in the United States alone. According to Peter Jackson of Advocates for the Reform of Prescription Opioids:

"Pharmaceutical firms are most interested in profits 

even if it means fostering further addiction 

among the American public."

("Experts Warn of Dangers of Zohydro, a New Pain Killer," 

http://www.fitnesshealth101.com/news, December 28 2011)

With a new powerful and addictive prescription painkiller coming on the horizon, it’s important for consumers to inform themselves of the dangers of opiate narcotics. I believe in order to avoid genix-cide, we should lobby to keep Zohydro and other new and similar hydrocodone products off the market. 

Many greedy doctors and others involved in the illegal distribution of drugs will use these products to deliberately addict and, subsequently, destroy the masses. We simply do not need them.